Compare Stitch Fix Inc (SFIX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs GeneDx Holdings Corp — how do they compare? Stitch Fix Inc trades at $2.74 (market cap $366.07M), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 5.5× Stitch Fix Inc's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 5,152,008). Which is the better fit depends on your goals — on Pluang, investors hold Stitch Fix Inc for 31 Days and GeneDx Holdings Corp for 19 Days on average.
| SFIX | WGS | |
|---|---|---|
Market Cap | $366.07M | $2.02B |
Volume | 5,152,008 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.64 | $167.51 |
52-Week Low | $2.16 | $34.51 |
Typical Hold Time | 31 Days | 19 Days |
Enterprise Value | $261.88M | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $2.73, up 2.25% today, but remains under pressure with a bearish technical signal. Recent Q4 2026 earnings showed a narrower loss than expected, but revenue missed estimates and weak FY2027 guidance triggered an 18% stock drop. The company is navigating a challenging consumer environment while leveraging AI personalization to boost engagement. Fundamentals show improving net loss margins, but negative ROE and ROA persist.
The outlook is cautious. While cost controls are improving losses, declining active clients and soft revenue guidance pose headwinds. Analyst consensus is a $3.40 price target with a 'Hold' bias. Key risks include execution on growth initiatives, high client acquisition costs, and ongoing legal investigations. The stock offers speculative appeal if turnaround gains traction, but near-term volatility is likely.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
